SubsidieMeestersA prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetime
GrOwnValve aims to revolutionize heart valve technology by creating lifelong autologous valves from patients' own tissue using 3D printing, reducing rejection and the need for multiple surgeries.
Projectdetails
Introduction
Each year, 400,000 people are born with heart valve defects worldwide. Moreover, in the western world, 1 in 8 healthy adults will develop a heart valve problem during their lifetime.
Current Challenges
Current artificial heart valves made from animal or human donor tissue carry a high risk of:
- Tissue rejection
- Degradation
- Calcification
These issues limit their lifespan to about 10 years, forcing patients to undergo risky cardiac re-surgery.
Pediatric Concerns
For children, no dedicated valve product exists. Thus, pediatric patients can endure 4-5 surgeries between the ages of 0-18 years as their bodies outgrow each replacement heart valve.
Innovation at GrOwnValve
At GrOwnValve, we have developed a paradigm shift in heart valve technology: the first autologous valve, grown from the patient's own tissue, crafted using medical imaging and a 3D printing technique.
Benefits of Our Solution
Our valve lasts a lifetime, eliminating tissue rejection and surgical risks associated with repeated surgery, such as:
- Bleeding
- Infection
- Death
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 3.611.043 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- GROWNVALVE GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Next-generation heart bypass grafts to naturally restore cardiovascular function.Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs. | EIC Accelerator | € 2.481.701 | 2022 | Details |
The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the marketThe Realheart TAH system aims to provide a permanent, efficient, and adaptable artificial heart solution for end-stage heart failure patients, with trials planned for validation. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A transcatheter functional valve replacement for tricuspid valve insufficiencyInnoventric's EIC project aims to clinically validate the Trillium, a minimally invasive transcatheter valve replacement for treating tricuspid regurgitation, improving patient outcomes. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
Next-generation heart bypass grafts to naturally restore cardiovascular function.
Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs.
The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the market
The Realheart TAH system aims to provide a permanent, efficient, and adaptable artificial heart solution for end-stage heart failure patients, with trials planned for validation.
A transcatheter functional valve replacement for tricuspid valve insufficiency
Innoventric's EIC project aims to clinically validate the Trillium, a minimally invasive transcatheter valve replacement for treating tricuspid regurgitation, improving patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
biomimetic engineered chordae tendineae for valve repair and regenerationThis project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration. | ERC Proof of... | € 150.000 | 2023 | Details |
Flow Controlled Prosthetic Heart ValvesStreamlineValve aims to develop a flow-controlled prosthetic heart valve that enhances durability and safety while reducing the need for anticoagulation therapy through optimized blood flow. | ERC Proof of... | € 150.000 | 2024 | Details |
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profilesProtego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications. | ERC Starting... | € 1.498.295 | 2024 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTsG-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease. | ERC Starting... | € 1.497.351 | 2022 | Details |
biomimetic engineered chordae tendineae for valve repair and regeneration
This project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration.
Flow Controlled Prosthetic Heart Valves
StreamlineValve aims to develop a flow-controlled prosthetic heart valve that enhances durability and safety while reducing the need for anticoagulation therapy through optimized blood flow.
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profiles
Protego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications.
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs
G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.